2月21日,中国国家药监局药品审评中心(CDE)官网最新公示,阿斯利康在国内递交了度伐利尤单抗注射液的新适应症上市申请(JXSS2500013/4),具体适应症暂未披露,本次申报为该药物在国内报上市的的第6项适应症。图源:CDE官网公开资料显示,度伐利尤单抗此前已在国内申报 5项适应症,其中3项已获批上市,包括III 期非小细胞肺癌(2019 年 12 月获批上市)、广泛期小细胞肺癌(2021 年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.